Approved PD-1 checkpoint-blockade antibodies have achieved remarkable success for treating patients with malignances such as melanoma, non-small cell lung cancer, and renal cell carcinoma [12, 13, 29]. The gene discussed is PDCD1; the disease is non-small cell lung carcinoma.